In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
685: Brain ‘Organoids’: Lab-Grown Cell Clusters Model Brain Functions
687: The Lasting Allure Of Shackleton’s ‘Endurance’
684: How Close Are We To Answers About Aliens?
686: NASA Delays Crewed Moon Missions | Top Technologies To Watch In 2024
683: To Get Ready For Mars, NASA Studies How The Body Changes In Space
682: Science Journalism Is Shrinking–Along With Public Trust In Science
680: (Part 2) Endangered Species Act At 50: Orchids And Red Wolves
679: (Part 1) Endangered Species Act at 50: Hawaiian Land Snails
681: Solar Activity Flares Up In 2024 | Underground Hydrogen Reserves And Clean Energy
678: SciFri Reads ‘The Alchemy Of Us’
677: SciFri Reads ‘The Kaiju Preservation Society’
676: Star Trek’s Science Advisor Reveals The Real Astrophysics On Screen
675: A Mathematician Asks ‘Is Math Real?’
674: Unmasking Owls’ Mysteries | Why It Feels So Good To Eat Chocolate
673: SciFri Reads ‘The Best American Science and Nature Writing 2023’
672: The Unseen World Of Seaweeds | Should 'Dark Fungi' Species Get Names?
672: How 'Panda Diplomacy' Led To Conservation Success
671: Music’s Emotional Power Can Shape Memories—And Your Perception Of Time
670: Top Science News Stories of 2023 | Solar Panels In Historic Cape Cod
669: Pennsylvania Drug Laws May Limit Syringe Services | These Romance Novels Represent Black Women In Science
Create your
podcast in
minutes
It is Free
The Modern West
Just Dumb Enough Podcast
Voices of Misery Podcast
House of Whimsical Terror
Stuff You Should Know
Timcast IRL